Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT05514769 Recruiting - Gastric Cancer Clinical Trials

Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer. Gastroesophageal reflux disease, postoperative quality of life, short term outcomes, and long term outcomes will be compared.

NCT ID: NCT05514158 Recruiting - Gastric Cancer Clinical Trials

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Start date: September 28, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, dose-escalation phase I clinical study.This study aimed to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical efficacy of RC48-ADC combined with RC98 in subjects with advanced gastric cancer.Which will provide a reference basis for dose confirmation in subsequent clinical studies.

NCT ID: NCT05513144 Recruiting - Gastric Cancer Clinical Trials

Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer

Start date: December 24, 2021
Phase:
Study type: Observational

This study aims to evaluate the use of next generation sequencing (NGS) to detect circulating tumor DNA in advanced HER2 negative gastric cancer patients. The evaluation of the therapy efficacy for gastric cancer patients is usually evaluated by computer tomography scans with RECIST criteria that are performed every two months during the treatment. In this study, we will compare the monitoring of circulating tumor DNA with the results of CT scan according the RECIST criteria and the blood level of CEA and CA 19-9 tumor markers.

NCT ID: NCT05508126 Recruiting - Clinical trials for Gastric Cancer Stage

Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer

Start date: November 1, 2021
Phase:
Study type: Observational

Accurate preoperative staging of gastric cancer is of major importance for guiding therapeutic decision-making, preventing both under- and over-treatment. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in gastric cancer.

NCT ID: NCT05498766 Recruiting - Gastric Cancer Clinical Trials

Effect and Safety of Adjuvant Huaier Granule Versus Standard Chemotherapy Regimens in Gastric Cancer Patients

Start date: October 12, 2023
Phase:
Study type: Observational

This is a prospective, multi-center, observational study. The purpose of this study is to evaluate the efficacy and safety of Huaier Granule versus standard chemotherapy regimens in the postoperative adjuvant treatment of resectable stage II-III gastric cancer.

NCT ID: NCT05497739 Recruiting - Gastric Cancer Clinical Trials

Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

Peritoneal metastasis is a major pattern of gastric cancer recurrence and predicts poor prognosis. In our previous study, we developed a next-generation sequencing technology to detect minimal residual cancer cells in peritoneal lavage fluid with a personalized assay profiling tumor-specific mutations in patients with gastric cancer. With this technology, we predicted all the cases that developed peritoneal metastasis in patients with pT4 disease with 100% sensitivity and 91% specificity. Based on this result, a prospective phase 2 clinical trial is designed to evaluate the efficacy of adjuvant intraperitoneal chemotherapy in patients with positive cancer cell DNA detected in peritoneal lavage fluid by our personalized tumor-specific mutation profiling assay.

NCT ID: NCT05494086 Recruiting - Gastric Cancer Clinical Trials

Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Dual-port laparoscopic gastrectomy (DPLG) has been widely performed in recent years for treating gastric cancers. The present study explore the safety and effect of dual-port laparoscopic distal gastrectomy (DPLDG).

NCT ID: NCT05494060 Recruiting - Gastric Cancer Clinical Trials

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

EXPLORING
Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks/cycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma.

NCT ID: NCT05489250 Recruiting - Pancreatic Cancer Clinical Trials

The PLATON Network

PLATON
Start date: October 28, 2020
Phase:
Study type: Observational

The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.

NCT ID: NCT05470452 Recruiting - Gastric Cancer Clinical Trials

Validating the Safety and Effectiveness of ENDOANGEL Upper Gastrointestinal Endoscope Image Auxiliary Diagnostic Software

Start date: July 28, 2021
Phase: N/A
Study type: Interventional

The upper Gastrointestinal Endoscope Image Auxiliary Diagnostic Software developed by Wuhan ENDOANGEL Medical Technology Co., Ltd. is used for the identification of gastric cancer in endoscopic magnification mode in definitive images to assist in the diagnosis of upper gastrointestinal gastric cancer lesions. The aim of this study is to evaluate the safety and effectiveness of the software in clinical use.